Skip to main content

View full-text article in PMC

. 2016 Mar;22(3):10.18553/jmcp.2016.22.3.219. doi: 10.18553/jmcp.2016.22.3.219

TABLE 3.

Medication Compliance (MPR) and Persistence (PDC) for First-Line Therapies for mRCC (N = 476)

Medication	MPR						PDC
	Medicare		Commercial		Total		Medicare		Commercial		Total
	n	MPR ≥ 80%	n	MPR ≥ 80%	n	MPR ≥ 80%	n	PDC ≥ 80%	n	PDC ≥ 80%	n	PDC ≥ 80%
Injectable
Bevacizumab	8	62.5%	5	60.0%	13	61.5%	12	75.0%	5	60.0%	17	70.6%
Temsirolimus	64	67.2%	11	81.8%	75	69.3%	71	76.1%	11	90.9%	86	78.0%
						P = 0.58^a						P = 0.51^a
Oral
Everolimus	12	75.0%	3	66.7%	15	73.3%	15	80.0%	4	100.0%	19	84.2%
Pazopanib	31	77.4%	6	83.3%	37	78.4%	44	88.6%	6	83.3%	50	88.0%
Sorafenib	49	65.3%	6	83.3%	55	67.3%	59	81.4%	7	85.7%	66	81.8%
Sunitinib	147	81.0%	48	79.2%	195	80.5%	186	91.9%	48	87.5%	234	91.0%
						P = 0.21^a						P = 0.19^a
Total injectable					88	68%					99	77%
Total oral					302	77%					369	89%
						P = 0.75^a						P = 0.002^a

^aP values were calculated by chi-square test (P < 0.05 was considered significant).

MPR = medication possession ratio; mRCC = metastatic renal cell carcinoma; PDC = proportion of days covered.